A pharmacoeconomic evaluation comparing loperamide (lop) versus octreotide (oct) in the treatment of chemotherapy induced diarrhoea - A payer perspective

被引：0
|
作者：
Nayak, Subhranshu S. [1 ]
Mohanty, Srikanta [1 ]
机构：
[1] SCB Med Coll, Dept Pharmacol, Cuttack, Odisha, India
来源：
INDIAN JOURNAL OF PHARMACOLOGY | 2013年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S210 / S210
页数：1
相关论文
共 18 条
  • [1] Octreotide treatment of chemotherapy-induced diarrhoea
    Ginopoulos, P
    Papagiannis, T
    Safridi, C
    Karvelas, F
    Spyropoulos, K
    Papadas, T
    Gogos, C
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 182 - 183
  • [2] SUBCUTANEOUS OCTREOTIDE VERSUS ORAL LOPERAMIDE IN THE TREATMENT OF DIARRHEA FOLLOWING CHEMOTHERAPY
    GEBBIA, V
    CARRECA, I
    TESTA, A
    VALENZA, R
    CURTO, G
    CANNATA, G
    BORSELLINO, N
    LATTERI, MA
    CIPOLLA, C
    FLORENA, M
    GEBBIA, N
    ANTI-CANCER DRUGS, 1993, 4 (04) : 443 - 445
  • [3] OCTREOTIDE VERSUS LOPERAMIDE IN THE TREATMENT OF FLUOROURACIL-INDUCED DIARRHEA - A RANDOMIZED TRIAL
    CASCINU, S
    FEDELI, A
    FEDELI, SL
    CATALANO, G
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 148 - 151
  • [4] Role of octreotide in the treatment of chemotherapy induced diarrhoea in colorectal cancer: A systematic literature review
    Bhattacharya, S.
    Vijayasekhar, C.
    Mathew, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [5] A RANDOMIZED, DOSE-ESCALATION TRIAL OF OCTREOTIDE VERSUS LOPERAMIDE FOR CHEMOTHERAPY-INDUCED DIARRHEA IN BONE-MARROW TRANSPLANT AND LEUKEMIA PATIENTS
    GELLER, RB
    TOPPING, DL
    GILMORE, CE
    DIX, SP
    DAVIDSON, TG
    LIN, LS
    HOLLAND, HK
    WINGARD, JR
    SARAL, R
    BLOOD, 1993, 82 (10) : A419 - A419
  • [6] RANDOMIZED TRIAL OF LOPERAMIDE VERSUS DOSE-ESCALATION OF OCTREOTIDE ACETATE FOR CHEMOTHERAPY-INDUCED DIARRHEA IN BONE-MARROW TRANSPLANT AND LEUKEMIA PATIENTS
    GELLER, RB
    GILMORE, CE
    DIX, SP
    LIN, LS
    TOPPING, DL
    DAVIDSON, TG
    HOLLAND, HK
    WINGARD, JR
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 50 (03) : 167 - 172
  • [7] A HEALTH TECHNOLOGY ASSESSMENT OF A PROPOSED BIOSIMILAR FOR THE TREATMENT OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A UNITED STATES PAYER PERSPECTIVE
    Vaidya, N.
    Cosler, L.
    VALUE IN HEALTH, 2014, 17 (03) : A88 - A88
  • [8] ECONOMIC EVALUATION OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR CHRONIC-WOUND TREATMENT FROM THE PUBLIC PAYER PERSPECTIVE
    Tolentino, A. C.
    Murta, L.
    Pereira, N.
    VALUE IN HEALTH, 2013, 16 (07) : A704 - A704
  • [9] Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: Stereotactic radiosurgery versus surgical resection
    Duong Anh Vuong
    Rades, Dirk
    van Eck, Albertus T. C.
    Horstmann, Gerhard A.
    Busse, Reinhard
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (03) : 276 - 284
  • [10] DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA: A HEALTH ECONOMIC EVALUATION
    Finek, J.
    Holubec, L.
    Wiesnerova, A.
    Pav, Z.
    Dusek, L.
    TUMOR BIOLOGY, 2010, 31 : S102 - S103
12